tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Day One price target lowered to $25 from $36 at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $25 from $36 and keeps a Buy rating on the shares following the Q2 report. The firm reduced estimates for the Ojemda launch.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1